4 - RENOVARO INC. (0001527728) (Issuer)

4 - RENOVARO INC. (0001527728) (Issuer)

4 - RENOVARO INC. (0001527728) (Issuer)

4 - RENOVARO INC. (0001527728) (Issuer)

3 - RENOVARO INC. (0001527728) (Issuer)

3 - RENOVARO INC. (0001527728) (Issuer)

4 - RENOVARO INC. (0001527728) (Issuer)

3 - RENOVARO INC. (0001527728) (Issuer)

4 - RENOVARO INC. (0001527728) (Issuer)

3 - RENOVARO INC. (0001527728) (Issuer)

SC 13D/A - RENOVARO INC. (0001527728) (Subject)

SC 13D/A - RENOVARO INC. (0001527728) (Subject)

SC 13D/A - RENOVARO INC. (0001527728) (Subject)

SC 13D/A - RENOVARO INC. (0001527728) (Subject)

SC 13D/A - RENOVARO INC. (0001527728) (Subject)

SC 13G/A - RENOVARO INC. (0001527728) (Subject)

AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024. This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs are a key hallmark of cancer and can be used in cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. "The research demonstrates that Oxford Nanopor

Supermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member SlateRealignment of Resources to Optimize and Commercialize RenovaroCube, the Company's Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies Newly Appointed Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and TreatmentRestructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer

AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube's AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions. Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in h

AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based. Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: "We were pleased to be engaged to make an assessment of the AI platform; this is exactly

AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024. "Combined, the findings that will be showcased represent key steps along the developmental pathway of Cube's "go-to-market" strategy for its open-source AI platform as a service provider to many potential private sector partners and (academic) hospitals, as well as commercializing proprietary diagnostic products. This is only the beginning of our journ

AMSTERDAM, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB. Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology for multi-omics and multi-modal data analysis, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes, beginning with cancer. "Newly

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ:RENB) (the "Company") announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage. "We appreciate confidence in the Company demonstrated by the investors," said the Hon. Mark Dybul, MD, CEO. "We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars." Forward-Looking Statements Statements in this press release that are not st

LOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the independent validation any final contractual commitments are subject to approval from both executive boards. This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Ca

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (NASDAQ:RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer. Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these lim

LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and mon

Gainers Kineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million. Brainstorm Cell (NASDAQ:BCLI) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million. Can Fite Biofarma (AMEX:

Renovaro, Inc. (NASDAQ:RENB) (the "Company") announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant coverage. "We appreciate confidence in the Company demonstrated by the investors," said the Hon. Mark Dybul, MD, CEO. "We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars."

Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw

Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. Nanoviricides (AMEX:NNVC) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. Semler Scientific (NASDAQ:SMLR) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. TransCode Therapeutics (N

Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. Renovaro (NASDAQ:RENB) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. Altamira Therapeutics (NASDAQ:CYTO) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. Purple Biotech (NASDAQ:PPBT) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. P3 Health Partners (NASDAQ:PIII) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 millio

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Treace Medical Concepts, Inc. (NASDAQ:TMCI) On May 7, Treace Medical Concepts reported first-quarter financial results and is

RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (NASDAQ:RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer. Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts